Srihari Sritharan

Srihari Sritharan is an investment fellow at Kaleida Capital and head of business development at Beacon Biosignals. He did his PhD at Penn under Timothy Lucas building wireless somatosensory prosthetics for spinal cord injury patients, and produced the first chronic neural interface with the sensory nuclei in the brainstem. He later ran diligence at Acadia Pharmaceuticals on a $967 million RNA therapy collaboration with Stoke Therapeutics.